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S U M M A R Y
Objectives: We aimed to estimate the pooled vaccine effectiveness (VE) in children over ﬁve winters
through data linkage of two existing surveillance systems.
Methods: Five test-negative case–control studies were conducted from November to February during
the 2004/2005 to 2008/2009 seasons. Sentinel physicians from the Viral Surveillance Network enrolled
children aged 6–59 months with inﬂuenza-like illness to collect throat swabs. Through linking with a
nationwide vaccination registry, we measured the VE with a logistic regression model adjusting for age,
gender, and week of symptom onset. Both ﬁxed-effects and random-effects models were used in the
meta-analysis.
Results: Four thousand four hundred and ninety-four subjects were included. The proportion of
inﬂuenza test-positive subjects across the ﬁve seasons was 11.5% (132/1151), 7.2% (41/572), 23.9% (189/
791), 6.6% (75/1135), and 11.2% (95/845), respectively. The pooled VE was 62% (95% conﬁdence interval
(CI) 48–83%) in both meta-analysis models. By age category, VE was 51% (95% CI 23–68%) for those aged
6–23 months and 75% (95% CI 60–84%) for those aged 24–59 months.
Conclusions: Inﬂuenza vaccination provided measurable protection against laboratory-conﬁrmed
inﬂuenza among children aged 6–59 months despite variations in the vaccine match during the
2004/2005 to 2008/2009 inﬂuenza seasons in Taiwan.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Inﬂuenza viruses cause annual epidemics and the occasional
pandemic of acute respiratory disease, which pose a threat to the
health of the population.1 Vaccination is considered a priority in
public health departments and is an effective way to prevent
inﬂuenza-associated morbidity, mortality, and expense.2 Since* Corresponding authors.
E-mail addresses: mtliu@cdc.gov.tw (M.-T. Liu), jhchuang@cdc.gov.tw
(J.-H. Chuang).
1 Tel.: +886 2 2653 1108; fax: +886 2 2785 3944.
2 Tel.: +886 2 2391 8471; fax: +886 2 2391 8543.
http://dx.doi.org/10.1016/j.ijid.2014.11.011
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1998, the Department of Health in Taiwan has gradually endorsed
annual inﬂuenza vaccination campaigns to encourage susceptible
subjects, including the elderly, healthcare workers, poultry work-
ers, and young children, to receive free inﬂuenza immunization,
based on the recommendations of the Advisory Committee on
Immunization Practices in Taiwan.
The recommendation of universal inﬂuenza vaccination of
young children was not popular in many countries initially,
probably because of the absence of studies providing solid
evidence of effectiveness in the targeted population.3,4 During
the 2004/2005 inﬂuenza season, the Centers for Disease Control in
Taiwan (Taiwan CDC) started to vaccinate groups of children aged
6–23 months; this program was extended to those aged 24–35ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the same opportunity to receive free inﬂuenza shots beginning in
October each year. In addition to the recommended groups, all
people could receive free inﬂuenza vaccination after December
1 each season in order to best utilize the inﬂuenza vaccine
resources and to increase the vaccine coverage of the entire
population.
It is important to determine the inﬂuenza vaccine effectiveness
(VE) after the implementation of such a program. Previous studies
have encouraged large studies to assess the impact of inﬂuenza
vaccination on children in terms of speciﬁc outcome measure-
ments.5,6 Furthermore, multiyear studies are preferred for
estimating robust inﬂuenza VE over time through a meta-analysis
methodology.7,8 The Taiwan CDC has successfully coordinated a
laboratory-based surveillance network for inﬂuenza virus for all
ages since 2000 and established the National Immunization
Information System (NIIS) for children aged <6 years in 2003.9
By using the retrospective laboratory-conﬁrmed inﬂuenza surveil-
lance data and linking these to individual vaccination records, we
were able to rapidly and efﬁciently demonstrate the inﬂuenza VE
in children for the 2004/2005 to 2008/2009 seasons.
Previous reports have demonstrated inﬂuenza VE using
routinely collected laboratory and/or surveillance data and directly
pooling results from multiple years to provide the overall VE.10–12
In this study, we implemented a ﬁxed-effects and a random-effects
meta-analysis of case–control studies to estimate the pooled VE for
children aged 6–59 months across the ﬁve consecutive inﬂuenza
seasons, and considered the variation in antigenic match across
seasons and epidemics year by year as the heterogeneity between
studies. Such effectiveness studies of inactivated inﬂuenza vaccine
among young children could assist public health sectors in
reassessing the current national inﬂuenza vaccination strategy
for the target groups, especially when vaccine match varies year to
year.
2. Subjects and methods
2.1. Study population
Children aged 6–59 months with an inﬂuenza-like illness (ILI)
during the November to February winter epidemics over ﬁve
seasons from 2004/2005 to 2008/2009 were investigated. The Viral
Surveillance Network required sentinel physicians to collect throat
or nasal swabs among verbally consenting ILI patients regardless of
the patient’s inﬂuenza vaccination status and underlying medical
conditions. ILI was deﬁned as a body temperature 38 8C plus one
of the following four clinical manifestations: cough, sore throat,
hoarseness and running nose, or headache and myalgia/fatigue.
This study was initiated as a public health response and used
routinely collected surveillance data and vaccination records to
assess inﬂuenza VE. The Taiwan CDC determined these activities to
be non-research and thus the study did not require review by an
institutional review board.
2.2. Viral surveillance network and virological testing
The Viral Surveillance Network coordinated by the Taiwan CDC
was started in October 2000; it comprises 10–13 collaborating
laboratories (the number is affected by the annual budget) and
aims to survey and isolate nationwide circulating viruses related to
respiratory tract infections year-round.9 Clinical specimens
obtained from nasal or throat swabs were collected by the sentinel
physicians and sent to the local collaborating laboratories for virus
identiﬁcation using viral culture and/or reverse transcriptase PCR.
Methods of virus isolation have been described previously.13 The
Taiwan CDC collected and analyzed these results on a weekly basisand posted this information on their website. The antigenic match
between vaccine and circulating strains in each season was
evaluated by hemagglutination inhibition (HAI) assay.
2.3. Determination of case and control subjects
Children whose specimens tested positive for laboratory-
conﬁrmed inﬂuenza infection during the study periods were
deﬁned as case subjects. Control subjects were those with the same
symptoms but who were negative for inﬂuenza. For cases and
controls, information about age, sex, week of symptom onset, and
personal identiﬁers were obtained from the reports submitted by
the sentinel physicians.
2.4. Inﬂuenza vaccination status
Information on the inﬂuenza vaccination status of the subjects
was obtained from the NIIS, which was established by the Taiwan
CDC to collect vaccination records for children at a national level.
Children were classiﬁed as vaccinated if they had received one or
more vaccine doses in the current inﬂuenza season and it was
administered 14 days before the onset of ILI. Children were
classiﬁed as unvaccinated for the given season if they were not
vaccinated in that study season or if they had received the ﬁrst
vaccine dose within 14 days before respiratory tract infection. In
this study, we did not deﬁne the status of partially vaccinated
children because many inﬂuenza epidemic strains in Taiwan
become the vaccine strains 2–3 years later, as shown by
hemagglutination sequence comparisons.9,14 Therefore, children
aged 6–59 months were considered immunized if they had
received one or more vaccine doses in the current inﬂuenza season
regardless of previous inﬂuenza immunization history.
2.5. Statistical analysis
We linked the NIIS and National Viral Surveillance System using
the personal identiﬁer. We used a logistic regression model to
adjust for age, gender, and week of symptom onset, with the ﬁrst
week including November 1 and the last week including February
28 in the ﬁve different epidemic seasons.15,16 The adjusted odds
ratio (aOR) was used to model the association between inﬂuenza
vaccination and laboratory-conﬁrmed inﬂuenza-related medical
visits in each season. VE and 95% conﬁdence intervals (CI) were
estimated using the formula VE = (1  OR)  100%. Stratiﬁed VE
estimates were calculated according to age (6–23 months or 24–59
months) and adjusted for gender and week of symptom onset. We
used both a ﬁxed-effects model with inverse variance method and
a random-effects model with DerSimonian–Laird weighting
method17 to run the synthesis results. A forest plot was used to
display the estimated overall ORs and separate ORs in the ﬁve
epidemic seasons according to the two age groups.18 We used the
‘meta’ package for the R system for statistical computing to
implement the meta-analysis.19,20 Annual vaccination rates among
control groups were examined using the Cochran–Armitage test
for trend in SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA).
3. Results
In Taiwan, ﬁve winter epidemics occurred between November
2004 and February 2009, which were dominated by inﬂuenza A
H1N1 in 2005/2006, 2007/2008, and 2008/2009, inﬂuenza B in
2004/2005, and inﬂuenza B followed by inﬂuenza A H3N2 in 2006/
2007 (Figure 1, Table 1). Information on inﬂuenza activity obtained
from the Viral Surveillance Network demonstrated that positive
rates of inﬂuenza isolates for 6–59-month-old children varied each
winter; from high to low, these rates were 23.9% (189/791) in the
Figure 1. Nationwide laboratory-based inﬂuenza surveillance in Taiwan from July 2004 to June 2009 is illustrated. Five winter epidemics occurred between November
2004 and February 2009. Vaccine match: The antigenic match between recommended vaccines and circulating viruses in each season was evaluated using the
hemagglutination inhibition (HAI) assay. The vaccine match (%) was calculated through the ratios of collected inﬂuenza A H1N1, inﬂuenza A H3N2, and inﬂuenza B viruses
and the respective antigenic match of three tested type/subtype viruses.
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11.2% (95/845) in the 2008/2009 season, 7.2% (41/572) in the 2005/
2006 season, and 6.6% (75/1135) in the 2007/2008 season
(Table 2). Furthermore, matches between circulating and vaccine
inﬂuenza strains were analyzed based on HAI assays, and a range of
12–93% of inﬂuenza virus isolates were antigenically similar to
inﬂuenza vaccine strains during 2004/2005 to 2008/2009
(Figure 1).
VE was estimated in a total of 4494 children aged 6–59 months
for whom laboratory results and vaccination status were available
for the ﬁve winter epidemics. Table 2 shows the demographic
distribution of the cases and controls in each season. Categorized
according to epidemic, the sex distribution was similar among case
and control subjects; however, the proportion of subjects who
tested positive was signiﬁcantly higher in children aged 24–59
months (15.2%) than in those aged 6–23 months (6.1%). From 2004/
2005 through 2008/2009 seasons, annual vaccination rates amongTable 1
Antigenic characteristics of inﬂuenza viruses and vaccine strains from the 2004/
2005 to 2008/2009 seasons
Season
and type
or subtype
Vaccine component Circulating strains
2004/2005
H1N1 A/New Caledonia/20/99-like -
H3N2 A/Fujian/411/2002-like A/California/7/2004(H3N2)-like
B B/Shanghai/361/2002-like B/Malaysia/2506/2004-like*
B/Shanghai/361/2002-like*
2005/2006
H1N1 A/New Caledonia/20/99-like A/New Caledonia/20/99*
H3N2 A/California/7/2004-like A/Wisconsin/67/2005-like
B B/Shanghai/361/2002-like -
2006/2007
H1N1 A/New Caledonia/20/99 -
H3N2 A/Wisconsin/67/2005 or
A/Hiroshima/52/2005
A/Wisconsin/67/2005-like
B B/Malaysia/2506/2004 B/Malaysia/2506/2004-like*
2007/2008
H1N1 A/Solomon Islands/3/2006 A/Brisbane/59/2007-like*
H3N2 A/Wisconsin/67/2005 or
A/Hiroshima/52/2005
A/Brisbane/10/2007-like
B B/Malaysia/2506/2004 B/Florida/4/2006-like
2008/2009
H1N1 A/Brisbane/59/2007 A/Brisbane/59/2007-like*
H3N2 A/Brisbane/10/2007 A/Brisbane/10/2007-like
B B/Florida/4/2006-like B/Florida/4/2006-like
* Dominant types/subtypes during the given season.control groups in children aged 6–23 months were 66.6% (213/320),
61.8% (139/225), 57.1% (129/226), 41.0% (236/575), and 47.1% (115/
244), which were higher than the rates in those aged 24–59 months
(10.7% (75/699), 21.2% (65/306), 18.6% (70/376), 19.4% (94/485), and
19.0% (96/506)) (test for trend, p < 0.0001 and p < 0.001 for the two
age groups, respectively). Vaccine coverage rates among the control
groups were close to those in the corresponding population
nationwide. The national inﬂuenza vaccine coverage available for
children aged 6–23 months was 68.9% (260 499/377 933), 66.6%
(243 149/365 335), 60.3% (212 605/352 502), and 44.8% (150 675/
335 972) for seasons 2004/2005 to 2007/2008, respectively, which
were estimated through the NIIS database. The national vaccine
coverage changed to 48.2% (255 565/530 561) for children aged 6–35
months in the 2008/2009 season when the inﬂuenza vaccination
program was extended to those aged 24–35 months. Otherwise,
inﬂuenza was detected in 532 (11.8%) enrollees. Approximately
11.1% (59/532) of those who tested positive and 31.1% (1232/3962)
of those who tested negative had been vaccinated.
The pooled estimate of VE for children aged 6–59 months
during 2004/2005 to 2008/2009 was 62% (95% CI 48–83%) using
the meta-analysis method (Figure 2). By age category (6–23
months and 24–59 months), the VE estimates were 51% (95% CI
23–68%) and 75% (95% CI 60–84%) for those aged 6–23 months and
24–59 months, respectively. The I2 value of 0% possibly indicates
that statistical heterogeneity was not observed across the ﬁve
winter epidemics, and across the age ranges of 6–23 months and
24–59 months (Figure 2). The VE estimates were higher among
those aged 24–59 months than among those aged 6–23 months
across the ﬁve seasons.
4. Discussion
In this study, we found clear evidence that the current public
health policy to reduce laboratory-conﬁrmed inﬂuenza among
young children through immunization is effective. The linkage of
routinely collected data is considered an efﬁcient method for
estimating inﬂuenza vaccine effectiveness more accurately.21,22
We successfully demonstrated an efﬁcient way to evaluate the
inﬂuenza VE for each winter epidemic through data linkage of two
already established systems in the public health sector and used
meta-analysis to estimate the pooled VE for children aged 6–59
months over consecutive seasons.
Meta-analysis could be appropriate when a group of studies is
sufﬁciently homogeneous in terms of participants, interventions,
and outcomes to provide a meaningful summary.23 The reason we
Table 2
Characteristics of inﬂuenza-positive case subjects and inﬂuenza-negative control
subjects according to inﬂuenza season, 2004/2005 through 2008/2009
Characteristics Cases Controls p-Value
2004/2005 (n = 132) (n = 1019)
Gender 0.33
Male 71 53.8% 488 47.9%
Female 54 40.9% 449 44.1%
Unknown 7 5.3% 82 8.0%
Age group <0.01
6–23 months 11 8.3% 320 31.4%
24–59 months 121 91.7% 699 68.6%
Vaccination status <0.01
Vaccinated 12 9.1% 288 28.3%
Unvaccinated 120 90.9% 731 71.7%
2005/2006 (n = 41) (n = 531)
Gender 0.85
Male 21 51.2% 295 55.6%
Female 19 46.3% 226 42.6%
Unknown 1 2.4% 10 1.9%
Age group <0.01
6–23 months 4 9.8% 225 42.4%
24–59 months 37 90.2% 306 57.6%
Vaccination status <0.01
Vaccinated 3 7.3% 204 38.4%
Unvaccinated 38 92.7% 327 61.6%
2006/2007 (n = 189) (n = 602)
Gender 0.29
Male 109 57.7% 355 59.0%
Female 80 42.3% 240 39.9%
Unknown 0 0.0% 7 1.2%
Age group <0.01
6–23 months 45 23.8% 226 37.5%
24–59 months 144 76.2% 376 62.5%
Vaccination status <0.01
Vaccinated 25 13.2% 199 33.1%
Unvaccinated 164 86.8% 403 66.9%
2007/2008 (n = 75) (n = 1060)
Gender 0.40
Male 46 61.3% 580 54.7%
Female 28 37.3% 473 44.6%
Unknown 1 1.3% 7 0.7%
Age group <0.01
6–23 months 28 37.3% 575 54.2%
24–59 months 47 62.7% 485 45.8%
Vaccination status <0.01
Vaccinated 8 10.7% 330 31.1%
Unvaccinated 67 89.3% 730 68.9%
2008/2009 (n = 95) (n = 750)
Gender 0.74
Male 52 54.7% 397 52.9%
Female 43 45.3% 353 47.1%
Unknown 0 0.0% 0 0.0%
Age group <0.01
6–23 months 16 16.8% 244 32.5%
24–59 months 79 83.2% 506 67.5%
Vaccination status <0.01
Vaccinated 11 11.6% 211 28.1%
Unvaccinated 84 88.4% 539 71.9%
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inﬂuenza VE across the ﬁve seasons of test-negative case–control
studies was to consider heterogeneity such as variation in the
antigenic match among years, inﬂuenza activity year by year,
vaccine policy changes over time with expansion of the age groups
targeted, and changes in the dominant circulating subtypes of
inﬂuenza virus, etc. Although statistical heterogeneity between
studies was not found in our study, to estimate VE across years using
a meta-analysis methodology might be a feasible and applicable
approach. Further stratiﬁed analysis of inﬂuenza type-speciﬁceffectiveness was not possible due to the small sample of
laboratory-conﬁrmed cases with virus type categories.
We estimated VE against laboratory-conﬁrmed inﬂuenza
infection using the test-negative case–control study design, which
is less susceptible to bias due to misclassiﬁcation of infection and
to confounding by health-seeking behavior, relative to traditional
case–control or cohort studies.15 Virological swab tests for
inﬂuenza as part of routine inﬂuenza surveillance to estimate
inﬂuenza VE more speciﬁcally in time and to compare VEs
internationally is encouraged and practiced in many countries.24
Recent studies have suggested that vaccine-induced protection
against inﬂuenza may decline over time among young children and
older adults in the test-negative case–control study design.25,26
Nunes et al. raised the issue of the best inﬂuenza-negative control
group to use in the test-negative study design.27 They observed
that a VE difference existed when choosing a non-inﬂuenza virus
control group and a pan-negative control group. Further studies
should be conducted to clarify such important issues. Another
challenge exists in establishing and maintaining the quality of the
vaccination register for vaccination programs, especially for annual
inﬂuenza vaccinations; such a register will provide information for
resource allocation, comprehensive evaluation, and a timely
response to all vaccine-preventable diseases.28
Our ﬁndings demonstrated a signiﬁcant pooled VE of 51% (95%
CI 23–68%) in 6–23-month-old children over ﬁve seasons. Previous
reports have shown that inﬂuenza vaccines are effective in healthy
children against laboratory-conﬁrmed inﬂuenza, serologically
conﬁrmed inﬂuenza, and clinical illness by systematic meta-
analysis.29,30 A recent study reported by Yang et al. with a study
design similar to ours found an inﬂuenza VE against medically-
attended inﬂuenza illness of 16% for those aged 6–35 months in the
2012/2013 season.31 Evidence for VE against outcomes other than
laboratory-conﬁrmed inﬂuenza infection such as preventing
emergency department visits and hospitalizations for ILI in
children has been evaluated, although more robust evidence is
needed in the future.32 Nevertheless, few of these studies have
provided adequate evidence of inﬂuenza VE among children
younger than 2 years of age, who, without chronic or serious
medical conditions, are still at increased risk of hospitalization
during the inﬂuenza season.3,4,33–35 Findings regarding the efﬁcacy
and effectiveness of inactivated inﬂuenza vaccines in children
younger than 2 years are inconsistent.24 Although a smaller
reduction in laboratory-conﬁrmed inﬂuenza infection was shown
in this age group compared to those older than 2 years of age, the
clinical relevance and public health implications of routine
inﬂuenza vaccination for both age groups has been con-
ﬁrmed.3,30,36
Several factors may affect the efﬁcacy and effectiveness of
inﬂuenza vaccine, including (1) antigenic similarity between the
circulating and vaccine types or strains of inﬂuenza virus; (2)
speciﬁcity of the outcome measurement of VE; (3) yearly
variability in inﬂuenza illness rates; (4) host characteristics (e.g.,
age and underlying medical conditions) in relation to immune
responses; (5) vaccine coverage and herd immunity; and (6)
relatively small sample sizes for inﬂuenza-positive cases within
each stratum evaluated.7,30,33,37–41
Annual vaccination rates in children aged 6–23 months
appeared to decline over the study period. This might be explained
by the severe acute respiratory syndrome (SARS) outbreaks in
Taiwan in 2003 and the introduction of the inﬂuenza vaccination
program in the 2004/2005 season for children aged 6–23 months.
Both of these events were an incentive to parents to have their
young children vaccinated with the inﬂuenza vaccine during the
early part of the study.
The possibility of cross-protection by inﬂuenza vaccine with a
suboptimal match has been debated.42 In years with a suboptimal
Figure 2. A ﬁxed-effects model with inverse variance method and a random-effects model with DerSimonian–Laird weighting method were applied to illustrate the vaccine
effectiveness by meta-analysis. Forest plots are used to display the estimated overall and separate adjusted odds ratios (aORs) and 95% conﬁdence interval (CI) in the ﬁve
epidemic seasons among children aged 6–59 months, stratiﬁed by age (6–23 months and 24–59 months). TE: log odds ratio; seTE: standard error of the log odds ratio; w:
weight.
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demonstrated.40,41 However, we found that only 12% of circulating
strains were similar to the vaccine strains in the 2007/2008 season,
but the VE was not as low as expected. The lack of signiﬁcant VE in
6–23-month-old children despite a high vaccine match in the
2005/2006 and 2008/2009 seasons might be related to the low ILI
rates, which were associated with the relatively small sample size
of children who tested positive for inﬂuenza.40 The seasonal
variations in terms of the proportions of case subjects in our
data obtained from the Viral Surveillance Network may reﬂect
the variable nature of inﬂuenza epidemics.38 The effect measure
modiﬁcation of age might be a concern in the analysis of vaccine
effectiveness; therefore it was appropriate to demonstrate both
age strata and age adjustment in the statistical models to estimate
vaccine effectiveness.43
Children aged 6 months to 8 years who have never received
seasonal inﬂuenza vaccines previously or who have received only
one dose in their ﬁrst year of vaccination should receive two doses
of seasonal inﬂuenza vaccine to be categorized as fully immunized
according to the recommendations of the US CDC.38,44 However,
inﬂuenza epidemic strains in Taiwan often circulate earlier thanvaccine strains recommended by the World Health Organization.9
Therefore, in this study, we deﬁned children aged 6–59 months
who had received at least one dose of seasonal inﬂuenza vaccine as
immunized regardless of their previous inﬂuenza vaccination
history. This may not be appropriate for infants aged 6–23
months.45 We speculate that the younger the children were, the
less chance they had had to experience the circulating local strains
in previous seasons for immune priming before vaccination, which
could have led to an underestimation of VE among younger
children if they were only partially immunized. Besides, high
vaccine coverage (50–70%) in children could possibly have an
impact on reducing inﬂuenza-related morbidity and mortality, not
only among the vaccinated children, but also in other age
groups.30,37 The challenge of increasing vaccine coverage still
exists.
The ﬁndings of this study are subject to several limitations.
First, children with underlying medical conditions are at even
greater risk of an adverse outcome related to inﬂuenza than
healthy children.33,39 Data linkage of the Viral Surveillance
Network and the NIIS did not provide personal medical informa-
tion, so we could not examine this issue. Second, only two
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resolve this problem, a validation study to conﬁrm the serology
indicator of an HAI antibody titer 1:40 after one dose of trivalent
inﬂuenza vaccine between two age strata might assist in
conﬁrming the immunization status in different geographic
areas.46 Third, there might have been selection bias with regard
to the vaccination status of subjects who were enrolled for
laboratory testing. It is possible that the testing of samples was
biased as this was done by the clinicians who provided the
inﬂuenza shot to the patient. However, in Taiwan, most patients
can see the doctor of their choice, therefore, most clinicians would
not know the patient’s inﬂuenza vaccination status. If sampling
was done on an informed basis such that the sentinel physician
collected fewer swabs from vaccinated ILI patients, a potential
biasing of estimates of effectiveness upwards might have
occurred.47 In the test-negative design for estimating inﬂuenza
VE, effectiveness does not vary by health-seeking behavior with
the assumption that the distribution of non-inﬂuenza causes of
acute respiratory infection does not vary by inﬂuenza vaccination
status.15 Therefore, cases and controls in our study probably had
similar characteristics with regard to their willingness to seek
medical care and their willingness to be swabbed, which could
eliminate the uncontrolled confounding between cases and
controls. The Viral Surveillance Network did not include all ILI
patients (those willing to be swabbed and those not willing to be
swabbed), thus it was not possible to determine the characteristics
of the children who were swabbed and those who were not. The
voluntary enrolment of swabbed participants in our study raises
the question of potential selection bias, which might bias the VE
estimation and limit the generalizability.3 Fourth, the impact of
repeated seasonal inﬂuenza vaccination on vaccine effectiveness
against inﬂuenza A and B virus has been debated, and further
studies are needed to provide more clear evidence.48,49 As this was
an observational study, residual confounding may still be present
despite different statistical models. We plan to investigate this
further in the future.50
In conclusion, our study rapidly and efﬁciently determined VE
across ﬁve inﬂuenza seasons using data linkage of immunization
records and viral surveillance data at the national level. Because
the annual burden of inﬂuenza illness and vaccine match could
inﬂuence VE, we combined studies using a case–control design
across consecutive inﬂuenza seasons using a novel method of
meta-analysis. Inﬂuenza vaccination provided measurable protec-
tion against laboratory-conﬁrmed inﬂuenza among children aged
6–23 months, 24–59 months, and the entire range of 6–59 months,
despite variation in vaccine match during the 2004/2005 to 2008/
2009 inﬂuenza seasons in Taiwan.
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